Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000538054 | SCV000637012 | uncertain significance | Brugada syndrome | 2022-09-27 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln1021*) in the SCN10A gene. It is expected to result in an absent or disrupted protein product. However, the current clinical and genetic evidence is not sufficient to establish whether loss-of-function variants in SCN10A cause disease. This variant is present in population databases (rs751252167, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with SCN10A-related conditions. ClinVar contains an entry for this variant (Variation ID: 463245). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003302814 | SCV003999213 | uncertain significance | Cardiovascular phenotype | 2023-06-16 | criteria provided, single submitter | clinical testing | The p.Q1021* variant (also known as c.3061C>T), located in coding exon 16 of the SCN10A gene, results from a C to T substitution at nucleotide position 3061. This changes the amino acid from a glutamine to a stop codon within coding exon 16. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. However, the evidence for this gene-disease relationship is limited; therefore, the clinical significance of this alteration is unclear. |